...
首页> 外文期刊>Pharmaceutical development and technology >Development of gastroretentive drug delivery system for cefuroxime axetil: in vitro and in vivo evaluation in human volunteers.
【24h】

Development of gastroretentive drug delivery system for cefuroxime axetil: in vitro and in vivo evaluation in human volunteers.

机译:头孢呋辛酯胃阻滞性药物输送系统的开发:在人类志愿者中的体外和体内评估。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this investigation was to develop the cefuroxime axetil sustained-release floating tablets to prolong the gastric residence time and compare their pharmacokinetic behavior with marketed conventional tablets (Zocef). The floating tablets were developed using polymers like HPMC K4M and HPMC K100M alone, and polymer combination of HPMC K4M and Polyox WSR 303 by effervescent technique. Tablets were prepared by slugging method and evaluated for their physical characteristics, in vitro drug release, and buoyancy lag time. The best formulation (F10) was selected based on in vitro characteristics and used in vivo radiographic and bioavailability studies in healthy human volunteers. All the formulations could sustain drug release for 12 h. The dissolution profiles were subjected to various kinetic release models and it was found that the mechanism of drug release followed Peppas model. The in vivo radiographic studies revealed that the tablets remained in stomach for 225 ± 30 min. Based on in vivo performance, the developed floating tablets showed superior bioavailability than Zocef tablet. Based on in vivo performance significant difference was observed between Cmax, tmax, t1/2, AUC0-∞, and mean residence time of test and reference (p<0.05). The increase in relative bioavailability of test was 1.61 fold when compared to reference.
机译:这项研究的目的是开发头孢呋辛酯酯缓释漂浮片以延长胃的停留时间,并将其药代动力学行为与市售的常规片剂(Zocef)​​进行比较。使用单独的聚合物(如HPMC K4M和HPMC K100M),以及通过泡腾技术将HPMC K4M和Polyox WSR 303的聚合物组合,开发了漂浮片剂。通过击打法制备片剂并评估其物理特性,体外药物释放和浮力滞后时间。根据体外特征选择最佳制剂(F10),并将其用于健康人类志愿者的体内放射照相和生物利用度研究。所有制剂均可维持药物释放12小时。对溶出曲线进行了各种动力学释放模型的研究,发现药物释放的机理遵循Peppas模型。体内放射学研究表明,片剂在胃中停留225±30分钟。基于体内性能,开发的漂浮片剂显示出比Zocef片剂更高的生物利用度。基于体内性能,观察到Cmax,tmax,t1 / 2,AUC0-∞与测试和参考的平均停留时间之间存在显着差异(p <0.05)。与参考相比,测试的相对生物利用度提高了1.61倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号